Fevipiprant

Summary

Fevipiprant (CHEMBL3137332) is a phase-3 clinical-stage small molecule targeting PTGDR2; indicated across 8 conditions including nasal cavity polyp and asthma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Targets: 1 (PTGDR2)
• Indications: 8 conditions
• Clinical trials: 16
• Chemistry: 426.4 Da · C19H17F3N2O4S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3137332
Name	Fevipiprant
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	23582412
Molecular formula	C19H17F3N2O4S
Molecular weight	426.4
InChIKey	GFPPXZDRVCSVNR-UHFFFAOYSA-N

SMILES: CC1=C(C2=C(N1CC3=C(C=C(C=C3)S(=O)(=O)C)C(F)(F)F)N=CC=C2)CC(=O)O

IUPAC name: 2-[2-methyl-1-[[4-methylsulfonyl-2-(trifluoromethyl)phenyl]methyl]pyrrolo[2,3-b]pyridin-3-yl]acetic acid

Also known as: Fevipiprant, NVP-QAW039, QAW-039, QAW039, FEVIPIPRANT

Patent coverage: 114 distinct patent families (288 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 205 (71%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
PTGDR2	DP2 receptor	Antagonist	8.99	0%	Q9Y5Y4

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Prostaglandin D2 receptor 2.

Bioactivity

ChEMBL activities: 9 potent at pChembl ≥ 5 of 9 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
PTGDR2	9.4	IC50	0.4	nM	CHEMBL_ACT_17991257
PTGDR2	9.4	IC50	0.4	nM	CHEMBL_ACT_17991273
PTGDR2	8.99	Kd	1.02	nM	CHEMBL_ACT_17991338
PTGDR2	8.85	IC50	1.4	nM	CHEMBL_ACT_17991321
PTGDR2	8.59	IC50	2.6	nM	CHEMBL_ACT_17991319
PTGDR2	8.51	IC50	3.1	nM	CHEMBL_ACT_17991323
PTGDR2	8.4	Ki	4	nM	CHEMBL_ACT_16885537
PTGDR2	8.4	Ki	4	nM	CHEMBL_ACT_17991289
PTGDR2	7.72	IC50	19	nM	CHEMBL_ACT_16885557

Target pathways

Aggregated over 1 target gene(s): PTGDR2.

Top Reactome pathways

2 total, by targets touching each:

Pathway	Targets	Genes
Prostanoid ligand receptors	1	PTGDR2
G alpha (i) signalling events	1	PTGDR2

Dominant GO biological processes

GO term	Targets
chemotaxis	1
immune response	1
G protein-coupled receptor signaling pathway	1
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway	1
neuropeptide signaling pathway	1
calcium-mediated signaling	1
positive regulation of G protein-coupled receptor signaling pathway	1
cellular response to prostaglandin D stimulus	1
negative regulation of male germ cell proliferation	1
signal transduction	1

Indications & clinical

Indications

8 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
nasal cavity polyp	3	MONDO:0006314	EFO:1000391
asthma	3	MONDO:0004979	MONDO:0004979
atopic eczema	2	MONDO:0004980	EFO:0000274
allergic rhinitis	2	MONDO:0011786	EFO:0005854
chronic obstructive pulmonary disease	2	MONDO:0005002	EFO:0000341
liver disorder	1	MONDO:0005154	EFO:0001421
kidney failure	1	MONDO:0001106	HP:0000083

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 16.

Phase distribution

Phase	Trials
PHASE2	8
PHASE3	6
PHASE1	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02555683	PHASE3	COMPLETED	Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.
NCT02563067	PHASE3	COMPLETED	Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.
NCT03052517	PHASE3	TERMINATED	Study of Safety of QAW039 in Patients With Asthma Inadequately Controlled on Standard-of-care Asthma Treatment
NCT03215758	PHASE3	COMPLETED	Study of Efficacy and Safety of QAW039 When Added to Standard-of-care Asthma Therapy in Patients With Uncontrolled Asthma
NCT03226392	PHASE3	COMPLETED	Study of Efficacy and Safety of QAW039 When Added to Standard-of-care Asthma Therapy in Patients With Uncontrolled Asthma
NCT03681093	PHASE3	COMPLETED	Study of Efficacy of Fevipiprant in Patients With Nasal Polyposis and Asthma
NCT01437735	PHASE2	COMPLETED	Dose Finding Study for QAW039 in Asthma
NCT01545726	PHASE2	COMPLETED	Safety and Efficacy of QAW039 in Sputum Eosinophilia and Persistent Asthma
NCT01785602	PHASE2	COMPLETED	Efficacy and Safety Study of QAW039 in the Treatment of Patients With Moderate to Severe Atopic Dermatitis.
NCT01804400	PHASE2	COMPLETED	A Clinical Trial to Test How Well Two Drugs, QAW039 and Montelukast Work Both Individually and Together, to Target Allergic Rhinitis Using an Environmental Exposure Chamber
NCT01836471	PHASE2	COMPLETED	A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients
NCT03650400	PHASE2	TERMINATED	Pharmacokinetics, Safety and Tolerability of Fevipiprant Delivered Via a Once Daily Chewable Tablet in Children Aged 6 to < 12 Years With Asthma
NCT03810183	PHASE2	TERMINATED	A Proof-of-mechanism Study of Multiple, Oral Doses of Fevipiprant (QAW039) in COPD Patients With Eosinophilia
NCT03989635	PHASE2	WITHDRAWN	Mechanistic Study of Anti-inflammatory Effects of Fevipiprant in Patients With Eosinophilic Asthma.
NCT03048448	PHASE1	COMPLETED	Pharmacokinetics of Fevipiprant (QAW039) in Patients With Hepatic Impairment Compared to Matched Healthy Subjects
NCT03087942	PHASE1	COMPLETED	Pharmacokinetics and Safety of Fevipiprant in Patients With Renal Impairment Compared to Matched Healthy Subjects

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

10 molecules share ≥1 primary target. Top 10 by shared-target count:

Molecule	Source	Status	Shared targets
INDOMETHACIN	ChEMBL + PubChem	Phase 4 (approved)	PTGDR2
LAROPIPRANT	ChEMBL	Phase 4 (approved)	PTGDR2
RAMATROBAN	ChEMBL	Phase 4 (approved)	PTGDR2
SETIPIPRANT	ChEMBL	Phase 3	PTGDR2
TIMAPIPRANT	ChEMBL	Phase 3	PTGDR2
AZD1981	ChEMBL	Phase 2	PTGDR2
BI-671800	ChEMBL	Phase 2	PTGDR2
FENTIAZAC	ChEMBL	Phase 2	PTGDR2
QAV680	ChEMBL	Phase 2	PTGDR2
VIDUPIPRANT	ChEMBL	Phase 2	PTGDR2